PHARMACOECONOMIC ANALYSIS OF ROSUVASTATIN GENERICS
DOI:
https://doi.org/10.52340/jecm.2024.04.19Ключевые слова:
Rosuvastatin, statins, generics, pharmacoeconomic, analysisАннотация
Statins are quite old and one of the most well-studied drug groups. Evidence-based, reliable information on the efficacy and safety of statins from randomized controlled trials is essential. When selecting statins, they take into account such indicators as high efficiency in long-term therapy, safety, and availability. The aim of the research was the pharmacoeconomic analysis of rosuvastatin generics admitted to the Georgian pharmaceutical market. An assortment study of rosuvastatin generics registered in Georgia, taking into account pharmacoeconomic aspects (using the method of cost minimization); Analysis of qualitative/quantitative, local/episodic information. The assortment of rosuvastatin generics admitted to the Georgian pharmaceutical market is quite diverse, 19 names of rosuvastatin generic drugs manufactured by 18 companies are registered, including 2 locally produced; After determining the reference prices for rosuvastatin generics, in the case of a large part of them, the monthly cost varies from 9 to 20 GEL, however, in some cases from 20 to 80 GEL. However, the pharmacoeconomic analysis clearly states that the use of a high dose is more cost-effective.
Скачивания
Библиографические ссылки
Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012; 5:257–264.
Fragoulakis V., Kourlaba G., Maniadakis N. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece, Clinicoecon Outcomes Res. 2012; 4:135-143. https://doi.org/10.2147/CEOR.S31376
Hirsch M., O’Donnell John C., Jones P. Rosuvastatin is Cost-Effective in Treating Patients to Low-Density Lipoprotein-Cholesterol Goals Compared with Atorvastatin, Pravastatin and Simvastatin: Analysis of the Stellar Trial. Eur J Cardiovasc Prev Rehabil. 2005 Feb; 12(1):18-28.
Kozhanova I., Romanova II., Gavrilenko L., Sachek M. Pharmacoeconomic Analysis Of Rosuvastatin Use In Patients With Hypercholesterolemia In The Health Care Of Belarus. Value Health. 2014 Nov; 17(7):A491.
Hyoeun Kim, Chan Joo Lee, Donghoon Choi et al. Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin/J Lipid Atheroscler. 2020 May;9(2):283-290 https://doi.org/10.12997/jla.2020.9.2.283 .pISSN 2287-2892·eISSN 2288-2561
Rosuvastatin Market Outlook 2017-2032 /https://dataintelo.com/request-sample/249167.